Bio-Techne

Bio-Techne and its subsidiaries develop, manufacture and sell biotechnology life science reagents, instruments and services for the research and clinical diagnostic markets.Co.'s segments: Protein Sciences, which developes and manufactures purified proteins and reagent solutions, cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies; and Diagnostics and Genomics, which develops and manufactures diagnostic products, including Food and Drug Administration-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for Original Equipment Manufacturer.
  • TickerTECH
  • ISINUS09073M1045
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

Michael Waterhouse

Morningstar | Dropping Coverage of Bio-Techne

We are dropping coverage of Bio-Techne. We provide broad coverage of more than 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing. We expect to reinitiate coverage of Bio-Techne later in the year.

Michael Waterhouse

Dropping Coverage of Bio-Techne

We are dropping coverage of Bio-Techne. We provide broad coverage of more than 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing. We expect to reinitiate coverage of Bio-Techne later in the year. ...

Michael Waterhouse

Morningstar | Bio-Techne Under Review

We are placing Bio-Techne under review as we transfer coverage to a new analyst. We expect to publish a new fair value estimate in the second quarter.

Michael Waterhouse

Bio-Techne Under Review

We are placing Bio-Techne under review as we transfer coverage to a new analyst. We expect to publish a new fair value estimate in the second quarter....

Michael Waterhouse

Morningstar | Bio-Techne Posts Impressive Growth in Fiscal 2Q Results

Bio-Techne reported solid fiscal second-quarter results, and we may slightly increase our fair value estimate as we take a second look at our revenue growth forecast. The company posted impressive 11% organic growth during the quarter on an already difficult year-over-year comparison. The growth also appears broad-based, with double-digit growth in many critical instrument categories, like Western blot and ELISA. Based on recent results, we think the company will probably exceed our 10% organic growth forecast for the fiscal year. While the integration of acquisitions like Exosome have also li...

1 director sold

A director at Bio-Techne Corp sold 3,117 shares at 215.000USD and the significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

ValuEngine Rating and Forecast Report for TECH

MarketLine Department

Repligen Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Repligen Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Repligen Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantag...

GlobalData Department

Bio Techne Corp (TECH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Bio Techne Corp (Bio Techne), formerly Techne, develops, produces, and markets biotechnology products and scientific tools to understand biological processes and drive research. The company’s portfolio encompasses native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization. It offers Western blot, enzyme-linked immunosorbent assay, and biologics platform. Bio Techne also offers controls and calibrators for hematology clinical instruments. Bio Techne’s products find application in scienti...

GlobalData Department

Bio Techne Corp (TECH) - Medical Equipment - Deals and Alliances Profile

Summary Bio Techne Corp (Bio Techne), formerly Techne, develops, produces, and markets biotechnology products and scientific tools to understand biological processes and drive research. The company’s portfolio encompasses native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization. It offers Western blot, enzyme-linked immunosorbent assay, and biologics platform. Bio Techne also offers controls and calibrators for hematology clinical instruments. Bio Techne’s products find application in scienti...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A few Consumer Discretionary names continue to act well. The list is thinning of attractive names though. (ex. FOXF, UEIC, DECK, CHDN, WING, YUM, BOOT, RCI, POOL, DLTR, and AAN) • A number of Health Care Sector names are attractive. (ex. MASI, TFX, CNMD, STE, CRVL, LNTH, HAE, COO, WST, RGEN, ANIK, NEO, and TECH) • Attractive Technology and Services names include: MANH, CDNS, ANSS, AGYS, TTEC, CLGX, MMS, and KBR

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the 200-day moving average. This level is roughly 2,817 on the S&P 500 and roughly 1,000 on the S&P 600 Small Cap index. Some consolidation or a mild pullback is possible in the near-term, which we believe would help alleviate current overbought readings and allow for a more orderly and meaningful move higher. This constructive outlook is supported by the themes highlighted below: • Internals are healthy. The S&P 500 advance/decline line is advancing to new ...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch